https://www.selleckchem.com/products/c646.html
OBJECTIVES To analyse the population pharmacokinetics of colistin and to explore the relationship between colistin exposure and time-to-death. METHODS Patients included in the AIDA randomized controlled trial were treated with colistin for severe infections caused by carbapenem-resistant Gram-negative bacteria. All subjects received a 9MU loading dose, followed by a 4.5MU twice daily maintenance dose, with dose reduction if creatinine clearance (CrCL) 2 mg/L at steady-state, but only 66% at 4h after start of treatment. High colistin exposu
Like
Comment
Share
